Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD-7295
- Development stage
- Phase 1
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AZD-7295 is a small molecule inhibitor developed for the treatment of Hepatitis C virus (HCV) infection. It specifically targets and inhibits the HCV nonstructural protein 5A (NS5A), a protein essential for viral replication. The compound exhibits potent antiviral activity, particularly against HCV genotype 1b, with an EC50 of approximately 7 nM in replicon assays. Developed initially by Arrow Therapeutics and later by AstraZeneca, AZD‑7295 advanced to Phase 1 clinical trials to assess its safety, pharmacokinetics, and tolerability in healthy volunteers as well as combination studies in patients with chronic HCV infection. Despite promising preclinical potency, development was discontinued after early-phase clinical evaluation[1][2][3][4][6].
- Other names
- 929890-64-2UNII-102MC1467JUNII102MC1467JUNII 102MC1467J4-[5-(cyclopropanecarbonylamino)-2-(trifluoromethoxy)phenyl]-N-[4-[(4-propylsulfonylpiperazin-1-yl)methyl]phenyl]benzamide
02
Targets
NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))
Beyond the preview
Go deeper on AZD-7295.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD-7295.